Temple University Develops AI Digital Twins for ALS Patients

Temple University Develops AI Digital Twins for ALS Patients

Researchers at Temple Health and Temple University are developing artificial intelligence-powered digital twins to help predict disease progression in patients with amyotrophic lateral sclerosis (ALS), according to WHYY News.

The project creates virtual representations of individual ALS patients that simulate how the disease might progress and how different treatments could affect outcomes. Each digital twin incorporates a patient's health history, genetics, social determinants of health, vital signs, mobility levels, muscle strength, respiratory function, and other clinical data.

The AI program will be trained on data from global ALS health outcomes databases containing information from thousands of patients. By continuously updating the digital twin with current medical information from appointments and wearable devices, doctors could generate real-time predictions about when patients might need wheelchairs, feeding tubes, or more intensive care.

Why it matters

ALS manifests differently in each patient, making it extremely difficult for families to plan ahead. The disease typically kills within two to five years of diagnosis, leaving patients and caregivers struggling to make critical decisions about treatment, travel, and end-of-life care without reliable timelines. Digital twins could transform this uncertainty into actionable information, while also improving clinical trial design by potentially reducing the need for large placebo groups.

From Personal Loss to Research Innovation

The need for better predictive tools is deeply personal for many in the ALS community. Jodi O'Donnell-Ames, who lost her husband Kevin to ALS in 2001 when he was just 36, now runs Hope Loves Company, a nonprofit supporting families affected by the disease. She described the constant uncertainty families face: "Should I plan this trip, even though I have two little kids, this summer? Do you think my husband's going to be here next summer?"

Dr. Terry Heiman-Patterson, neurologist and director of the MDA/ALS Center of Hope at Temple University Lewis Katz School of Medicine, said the goal is to "anticipate, so I can intervene early" and "answer those questions in an intelligent way."

Beyond ALS Applications

Digital twin technology is already used in automotive manufacturing, urban water systems, and electrical grid management. In healthcare, the approach is gaining traction as AI systems become more sophisticated.

Heiman-Patterson noted that digital twins could improve clinical trial efficiency. Currently, about 50% of trial participants receive placebos, which is "frustrating to say the least" for patients who may only qualify for one trial during their disease course. If digital twin predictions could supplement placebo groups, fewer patients would need to be assigned to control arms.

Huanmei Wu, chair of the Department of Health Services Administration and Policy at Temple's Barnett College of Public Health, explained that doctors could use the system to simulate medication changes and ask, "How much longer do we need to prepare for the wheelchair or how much longer we need to prepare for the [feeding] tube?"

Researchers estimate the digital twin program will need two to six years before clinical testing, depending on funding for software development, AI engineering, data analysis, and storage. The team is pursuing state and federal grants and philanthropic partnerships.

These details were first reported by WHYY News.